Review



p-axl antibodies (y702)  (Cell Signaling Technology Inc)


Bioz Verified Symbol Cell Signaling Technology Inc is a verified supplier
Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Cell Signaling Technology Inc p-axl antibodies (y702)
    P Axl Antibodies (Y702), supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/p-axl+antibodies+(y702)/anti+axl/pm38886556-70-1-7
    Average 90 stars, based on 1 article reviews
    p-axl antibodies (y702) - by Bioz Stars, 2026-10
    90/100 stars

    Images

    Related Articles

    Activity Assay:

    Article Title: Aberrant activation of AXL may drive progression of squamous cell carcinoma in CLL patients: a mechanistic study with clinical implications.
    Article Snippet: BACKGROUND: Occurrence of squamous cell carcinoma (SCC) even in early-stage, untreated chronic lymphocytic leukemia (CLL) patients can be a significant morbidity issue with occasional transformation into metastatic skin lesions.. METHODS: CLL cells and extracellular vesicles (EVs) from CLL patients’ blood/plasma were purified and used.. Expression/activation of AXL and its functions in normal keratinocytes (HEKa) were assessed in vitro co-culture system and in SCC tissues.

    Article Title: (−)-Epigallocatechin gallate inhibits stemness and tumourigenicity stimulated by AXL receptor tyrosine kinase in human lung cancer cells
    Article Snippet: Anti-AXL (R&D Systems, Minneapolis, MN, USA), anti-p-AXL (Y702) (Cell Signaling Technology, Inc., Danvers, MA, USA), anti-SLUG (Cell Signaling Technology, Inc.), anti-ALDH1A1 (Santa Cruz, Biotechnology, Inc., Santa Cruz, CA, USA), and anti-α-tubulin (Cell Signaling Technology, Inc.) antibodies were used for the experiments.

    Article Title: Novel Axl-driven signaling pathway and molecular signature characterize high-grade ovarian cancer patients with poor clinical outcome
    Article Snippet: Abs against P-Axl(Y702) (rabbit), P-AKT(S473) (rabbit), anti-Mer (mouse), P-src (Y416), and anti-P-Tyrosine (P-Tyr-100) (mouse) were obtained from Cell Signaling Technology (New England BioLabs, Beverly, MA, USA); anti-Axl (goat), anti-FAK (rabbit), anti-Tyro-3 (goat), and anti-β1 and anti-p130Cas (mouse) from Santa Cruz Biotechnology (Santa Cruz, CA, USA); anti-α-tubulin (mouse) from Thermo Scientific (Fremont, CA, USA); anti-β-actin (rabbit) from Sigma-Aldrich (Saint Louis, MO, USA); anti-β3 from Abcam (Cambridge, UK); and anti-β4 from Millipore (Merck Millipore, Oxford, UK).

    Article Title: Novel Axl-driven signaling pathway and molecular signature characterize high-grade ovarian cancer patients with poor clinical outcome.
    Article Snippet: Abs against P-Axl(Y702) (rabbit), P-AKT(S473) (rabbit), anti-Mer (mouse), P-src (Y416), and anti-P-Tyrosine (P-Tyr-100) (mouse) were obtained from Cell Signaling Technology (New England BioLabs, Beverly, MA, USA); anti-Axl (goat), anti-FAK (rabbit), anti-Tyro-3 (goat), and anti-β1 and anti-p130Cas (mouse) from Santa Cruz Biotechnology (Santa Cruz, CA, USA); anti-α-tubulin (mouse) from Thermo Scientific (Fremont, CA, USA); anti-β-actin (rabbit) from SigmaAldrich (Saint Louis, MO, USA); anti-β3 from Abcam (Cambridge, UK); and anti-β4 from Millipore (Merck Millipore, Oxford, UK).

    Control:

    Article Title: Aberrant activation of AXL may drive progression of squamous cell carcinoma in CLL patients: a mechanistic study with clinical implications.
    Article Snippet: BACKGROUND: Occurrence of squamous cell carcinoma (SCC) even in early-stage, untreated chronic lymphocytic leukemia (CLL) patients can be a significant morbidity issue with occasional transformation into metastatic skin lesions.. METHODS: CLL cells and extracellular vesicles (EVs) from CLL patients’ blood/plasma were purified and used.. Expression/activation of AXL and its functions in normal keratinocytes (HEKa) were assessed in vitro co-culture system and in SCC tissues.

    Article Title: (−)-Epigallocatechin gallate inhibits stemness and tumourigenicity stimulated by AXL receptor tyrosine kinase in human lung cancer cells
    Article Snippet: Anti-AXL (R&D Systems, Minneapolis, MN, USA), anti-p-AXL (Y702) (Cell Signaling Technology, Inc., Danvers, MA, USA), anti-SLUG (Cell Signaling Technology, Inc.), anti-ALDH1A1 (Santa Cruz, Biotechnology, Inc., Santa Cruz, CA, USA), and anti-α-tubulin (Cell Signaling Technology, Inc.) antibodies were used for the experiments.

    Article Title: Novel Axl-driven signaling pathway and molecular signature characterize high-grade ovarian cancer patients with poor clinical outcome
    Article Snippet: Abs against P-Axl(Y702) (rabbit), P-AKT(S473) (rabbit), anti-Mer (mouse), P-src (Y416), and anti-P-Tyrosine (P-Tyr-100) (mouse) were obtained from Cell Signaling Technology (New England BioLabs, Beverly, MA, USA); anti-Axl (goat), anti-FAK (rabbit), anti-Tyro-3 (goat), and anti-β1 and anti-p130Cas (mouse) from Santa Cruz Biotechnology (Santa Cruz, CA, USA); anti-α-tubulin (mouse) from Thermo Scientific (Fremont, CA, USA); anti-β-actin (rabbit) from Sigma-Aldrich (Saint Louis, MO, USA); anti-β3 from Abcam (Cambridge, UK); and anti-β4 from Millipore (Merck Millipore, Oxford, UK).

    Article Title: Novel Axl-driven signaling pathway and molecular signature characterize high-grade ovarian cancer patients with poor clinical outcome.
    Article Snippet: Abs against P-Axl(Y702) (rabbit), P-AKT(S473) (rabbit), anti-Mer (mouse), P-src (Y416), and anti-P-Tyrosine (P-Tyr-100) (mouse) were obtained from Cell Signaling Technology (New England BioLabs, Beverly, MA, USA); anti-Axl (goat), anti-FAK (rabbit), anti-Tyro-3 (goat), and anti-β1 and anti-p130Cas (mouse) from Santa Cruz Biotechnology (Santa Cruz, CA, USA); anti-α-tubulin (mouse) from Thermo Scientific (Fremont, CA, USA); anti-β-actin (rabbit) from SigmaAldrich (Saint Louis, MO, USA); anti-β3 from Abcam (Cambridge, UK); and anti-β4 from Millipore (Merck Millipore, Oxford, UK).

    Western Blot:

    Article Title: Aberrant activation of AXL may drive progression of squamous cell carcinoma in CLL patients: a mechanistic study with clinical implications.
    Article Snippet: BACKGROUND: Occurrence of squamous cell carcinoma (SCC) even in early-stage, untreated chronic lymphocytic leukemia (CLL) patients can be a significant morbidity issue with occasional transformation into metastatic skin lesions.. METHODS: CLL cells and extracellular vesicles (EVs) from CLL patients’ blood/plasma were purified and used.. Expression/activation of AXL and its functions in normal keratinocytes (HEKa) were assessed in vitro co-culture system and in SCC tissues.

    Article Title: (−)-Epigallocatechin gallate inhibits stemness and tumourigenicity stimulated by AXL receptor tyrosine kinase in human lung cancer cells
    Article Snippet: Anti-AXL (R&D Systems, Minneapolis, MN, USA), anti-p-AXL (Y702) (Cell Signaling Technology, Inc., Danvers, MA, USA), anti-SLUG (Cell Signaling Technology, Inc.), anti-ALDH1A1 (Santa Cruz, Biotechnology, Inc., Santa Cruz, CA, USA), and anti-α-tubulin (Cell Signaling Technology, Inc.) antibodies were used for the experiments.

    Article Title: Novel Axl-driven signaling pathway and molecular signature characterize high-grade ovarian cancer patients with poor clinical outcome
    Article Snippet: Abs against P-Axl(Y702) (rabbit), P-AKT(S473) (rabbit), anti-Mer (mouse), P-src (Y416), and anti-P-Tyrosine (P-Tyr-100) (mouse) were obtained from Cell Signaling Technology (New England BioLabs, Beverly, MA, USA); anti-Axl (goat), anti-FAK (rabbit), anti-Tyro-3 (goat), and anti-β1 and anti-p130Cas (mouse) from Santa Cruz Biotechnology (Santa Cruz, CA, USA); anti-α-tubulin (mouse) from Thermo Scientific (Fremont, CA, USA); anti-β-actin (rabbit) from Sigma-Aldrich (Saint Louis, MO, USA); anti-β3 from Abcam (Cambridge, UK); and anti-β4 from Millipore (Merck Millipore, Oxford, UK).

    Article Title: Novel Axl-driven signaling pathway and molecular signature characterize high-grade ovarian cancer patients with poor clinical outcome.
    Article Snippet: Abs against P-Axl(Y702) (rabbit), P-AKT(S473) (rabbit), anti-Mer (mouse), P-src (Y416), and anti-P-Tyrosine (P-Tyr-100) (mouse) were obtained from Cell Signaling Technology (New England BioLabs, Beverly, MA, USA); anti-Axl (goat), anti-FAK (rabbit), anti-Tyro-3 (goat), and anti-β1 and anti-p130Cas (mouse) from Santa Cruz Biotechnology (Santa Cruz, CA, USA); anti-α-tubulin (mouse) from Thermo Scientific (Fremont, CA, USA); anti-β-actin (rabbit) from SigmaAldrich (Saint Louis, MO, USA); anti-β3 from Abcam (Cambridge, UK); and anti-β4 from Millipore (Merck Millipore, Oxford, UK).

    Knockdown:

    Article Title: Aberrant activation of AXL may drive progression of squamous cell carcinoma in CLL patients: a mechanistic study with clinical implications.
    Article Snippet: BACKGROUND: Occurrence of squamous cell carcinoma (SCC) even in early-stage, untreated chronic lymphocytic leukemia (CLL) patients can be a significant morbidity issue with occasional transformation into metastatic skin lesions.. METHODS: CLL cells and extracellular vesicles (EVs) from CLL patients’ blood/plasma were purified and used.. Expression/activation of AXL and its functions in normal keratinocytes (HEKa) were assessed in vitro co-culture system and in SCC tissues.

    Article Title: (−)-Epigallocatechin gallate inhibits stemness and tumourigenicity stimulated by AXL receptor tyrosine kinase in human lung cancer cells
    Article Snippet: Anti-AXL (R&D Systems, Minneapolis, MN, USA), anti-p-AXL (Y702) (Cell Signaling Technology, Inc., Danvers, MA, USA), anti-SLUG (Cell Signaling Technology, Inc.), anti-ALDH1A1 (Santa Cruz, Biotechnology, Inc., Santa Cruz, CA, USA), and anti-α-tubulin (Cell Signaling Technology, Inc.) antibodies were used for the experiments.

    Article Title: Novel Axl-driven signaling pathway and molecular signature characterize high-grade ovarian cancer patients with poor clinical outcome
    Article Snippet: Abs against P-Axl(Y702) (rabbit), P-AKT(S473) (rabbit), anti-Mer (mouse), P-src (Y416), and anti-P-Tyrosine (P-Tyr-100) (mouse) were obtained from Cell Signaling Technology (New England BioLabs, Beverly, MA, USA); anti-Axl (goat), anti-FAK (rabbit), anti-Tyro-3 (goat), and anti-β1 and anti-p130Cas (mouse) from Santa Cruz Biotechnology (Santa Cruz, CA, USA); anti-α-tubulin (mouse) from Thermo Scientific (Fremont, CA, USA); anti-β-actin (rabbit) from Sigma-Aldrich (Saint Louis, MO, USA); anti-β3 from Abcam (Cambridge, UK); and anti-β4 from Millipore (Merck Millipore, Oxford, UK).

    Article Title: Novel Axl-driven signaling pathway and molecular signature characterize high-grade ovarian cancer patients with poor clinical outcome.
    Article Snippet: Abs against P-Axl(Y702) (rabbit), P-AKT(S473) (rabbit), anti-Mer (mouse), P-src (Y416), and anti-P-Tyrosine (P-Tyr-100) (mouse) were obtained from Cell Signaling Technology (New England BioLabs, Beverly, MA, USA); anti-Axl (goat), anti-FAK (rabbit), anti-Tyro-3 (goat), and anti-β1 and anti-p130Cas (mouse) from Santa Cruz Biotechnology (Santa Cruz, CA, USA); anti-α-tubulin (mouse) from Thermo Scientific (Fremont, CA, USA); anti-β-actin (rabbit) from SigmaAldrich (Saint Louis, MO, USA); anti-β3 from Abcam (Cambridge, UK); and anti-β4 from Millipore (Merck Millipore, Oxford, UK).

    Cell Culture:

    Article Title: Aberrant activation of AXL may drive progression of squamous cell carcinoma in CLL patients: a mechanistic study with clinical implications.
    Article Snippet: BACKGROUND: Occurrence of squamous cell carcinoma (SCC) even in early-stage, untreated chronic lymphocytic leukemia (CLL) patients can be a significant morbidity issue with occasional transformation into metastatic skin lesions.. METHODS: CLL cells and extracellular vesicles (EVs) from CLL patients’ blood/plasma were purified and used.. Expression/activation of AXL and its functions in normal keratinocytes (HEKa) were assessed in vitro co-culture system and in SCC tissues.

    Article Title: (−)-Epigallocatechin gallate inhibits stemness and tumourigenicity stimulated by AXL receptor tyrosine kinase in human lung cancer cells
    Article Snippet: Anti-AXL (R&D Systems, Minneapolis, MN, USA), anti-p-AXL (Y702) (Cell Signaling Technology, Inc., Danvers, MA, USA), anti-SLUG (Cell Signaling Technology, Inc.), anti-ALDH1A1 (Santa Cruz, Biotechnology, Inc., Santa Cruz, CA, USA), and anti-α-tubulin (Cell Signaling Technology, Inc.) antibodies were used for the experiments.

    Article Title: Novel Axl-driven signaling pathway and molecular signature characterize high-grade ovarian cancer patients with poor clinical outcome
    Article Snippet: Abs against P-Axl(Y702) (rabbit), P-AKT(S473) (rabbit), anti-Mer (mouse), P-src (Y416), and anti-P-Tyrosine (P-Tyr-100) (mouse) were obtained from Cell Signaling Technology (New England BioLabs, Beverly, MA, USA); anti-Axl (goat), anti-FAK (rabbit), anti-Tyro-3 (goat), and anti-β1 and anti-p130Cas (mouse) from Santa Cruz Biotechnology (Santa Cruz, CA, USA); anti-α-tubulin (mouse) from Thermo Scientific (Fremont, CA, USA); anti-β-actin (rabbit) from Sigma-Aldrich (Saint Louis, MO, USA); anti-β3 from Abcam (Cambridge, UK); and anti-β4 from Millipore (Merck Millipore, Oxford, UK).

    Article Title: Novel Axl-driven signaling pathway and molecular signature characterize high-grade ovarian cancer patients with poor clinical outcome.
    Article Snippet: Abs against P-Axl(Y702) (rabbit), P-AKT(S473) (rabbit), anti-Mer (mouse), P-src (Y416), and anti-P-Tyrosine (P-Tyr-100) (mouse) were obtained from Cell Signaling Technology (New England BioLabs, Beverly, MA, USA); anti-Axl (goat), anti-FAK (rabbit), anti-Tyro-3 (goat), and anti-β1 and anti-p130Cas (mouse) from Santa Cruz Biotechnology (Santa Cruz, CA, USA); anti-α-tubulin (mouse) from Thermo Scientific (Fremont, CA, USA); anti-β-actin (rabbit) from SigmaAldrich (Saint Louis, MO, USA); anti-β3 from Abcam (Cambridge, UK); and anti-β4 from Millipore (Merck Millipore, Oxford, UK).

    Flow Cytometry:

    Article Title: Aberrant activation of AXL may drive progression of squamous cell carcinoma in CLL patients: a mechanistic study with clinical implications.
    Article Snippet: BACKGROUND: Occurrence of squamous cell carcinoma (SCC) even in early-stage, untreated chronic lymphocytic leukemia (CLL) patients can be a significant morbidity issue with occasional transformation into metastatic skin lesions.. METHODS: CLL cells and extracellular vesicles (EVs) from CLL patients’ blood/plasma were purified and used.. Expression/activation of AXL and its functions in normal keratinocytes (HEKa) were assessed in vitro co-culture system and in SCC tissues.

    Article Title: (−)-Epigallocatechin gallate inhibits stemness and tumourigenicity stimulated by AXL receptor tyrosine kinase in human lung cancer cells
    Article Snippet: Anti-AXL (R&D Systems, Minneapolis, MN, USA), anti-p-AXL (Y702) (Cell Signaling Technology, Inc., Danvers, MA, USA), anti-SLUG (Cell Signaling Technology, Inc.), anti-ALDH1A1 (Santa Cruz, Biotechnology, Inc., Santa Cruz, CA, USA), and anti-α-tubulin (Cell Signaling Technology, Inc.) antibodies were used for the experiments.

    Article Title: Novel Axl-driven signaling pathway and molecular signature characterize high-grade ovarian cancer patients with poor clinical outcome
    Article Snippet: Abs against P-Axl(Y702) (rabbit), P-AKT(S473) (rabbit), anti-Mer (mouse), P-src (Y416), and anti-P-Tyrosine (P-Tyr-100) (mouse) were obtained from Cell Signaling Technology (New England BioLabs, Beverly, MA, USA); anti-Axl (goat), anti-FAK (rabbit), anti-Tyro-3 (goat), and anti-β1 and anti-p130Cas (mouse) from Santa Cruz Biotechnology (Santa Cruz, CA, USA); anti-α-tubulin (mouse) from Thermo Scientific (Fremont, CA, USA); anti-β-actin (rabbit) from Sigma-Aldrich (Saint Louis, MO, USA); anti-β3 from Abcam (Cambridge, UK); and anti-β4 from Millipore (Merck Millipore, Oxford, UK).

    Article Title: Novel Axl-driven signaling pathway and molecular signature characterize high-grade ovarian cancer patients with poor clinical outcome.
    Article Snippet: Abs against P-Axl(Y702) (rabbit), P-AKT(S473) (rabbit), anti-Mer (mouse), P-src (Y416), and anti-P-Tyrosine (P-Tyr-100) (mouse) were obtained from Cell Signaling Technology (New England BioLabs, Beverly, MA, USA); anti-Axl (goat), anti-FAK (rabbit), anti-Tyro-3 (goat), and anti-β1 and anti-p130Cas (mouse) from Santa Cruz Biotechnology (Santa Cruz, CA, USA); anti-α-tubulin (mouse) from Thermo Scientific (Fremont, CA, USA); anti-β-actin (rabbit) from SigmaAldrich (Saint Louis, MO, USA); anti-β3 from Abcam (Cambridge, UK); and anti-β4 from Millipore (Merck Millipore, Oxford, UK).

    Staining:

    Article Title: Aberrant activation of AXL may drive progression of squamous cell carcinoma in CLL patients: a mechanistic study with clinical implications.
    Article Snippet: BACKGROUND: Occurrence of squamous cell carcinoma (SCC) even in early-stage, untreated chronic lymphocytic leukemia (CLL) patients can be a significant morbidity issue with occasional transformation into metastatic skin lesions.. METHODS: CLL cells and extracellular vesicles (EVs) from CLL patients’ blood/plasma were purified and used.. Expression/activation of AXL and its functions in normal keratinocytes (HEKa) were assessed in vitro co-culture system and in SCC tissues.

    Article Title: (−)-Epigallocatechin gallate inhibits stemness and tumourigenicity stimulated by AXL receptor tyrosine kinase in human lung cancer cells
    Article Snippet: Anti-AXL (R&D Systems, Minneapolis, MN, USA), anti-p-AXL (Y702) (Cell Signaling Technology, Inc., Danvers, MA, USA), anti-SLUG (Cell Signaling Technology, Inc.), anti-ALDH1A1 (Santa Cruz, Biotechnology, Inc., Santa Cruz, CA, USA), and anti-α-tubulin (Cell Signaling Technology, Inc.) antibodies were used for the experiments.

    Article Title: Novel Axl-driven signaling pathway and molecular signature characterize high-grade ovarian cancer patients with poor clinical outcome
    Article Snippet: Abs against P-Axl(Y702) (rabbit), P-AKT(S473) (rabbit), anti-Mer (mouse), P-src (Y416), and anti-P-Tyrosine (P-Tyr-100) (mouse) were obtained from Cell Signaling Technology (New England BioLabs, Beverly, MA, USA); anti-Axl (goat), anti-FAK (rabbit), anti-Tyro-3 (goat), and anti-β1 and anti-p130Cas (mouse) from Santa Cruz Biotechnology (Santa Cruz, CA, USA); anti-α-tubulin (mouse) from Thermo Scientific (Fremont, CA, USA); anti-β-actin (rabbit) from Sigma-Aldrich (Saint Louis, MO, USA); anti-β3 from Abcam (Cambridge, UK); and anti-β4 from Millipore (Merck Millipore, Oxford, UK).

    Article Title: Novel Axl-driven signaling pathway and molecular signature characterize high-grade ovarian cancer patients with poor clinical outcome.
    Article Snippet: Abs against P-Axl(Y702) (rabbit), P-AKT(S473) (rabbit), anti-Mer (mouse), P-src (Y416), and anti-P-Tyrosine (P-Tyr-100) (mouse) were obtained from Cell Signaling Technology (New England BioLabs, Beverly, MA, USA); anti-Axl (goat), anti-FAK (rabbit), anti-Tyro-3 (goat), and anti-β1 and anti-p130Cas (mouse) from Santa Cruz Biotechnology (Santa Cruz, CA, USA); anti-α-tubulin (mouse) from Thermo Scientific (Fremont, CA, USA); anti-β-actin (rabbit) from SigmaAldrich (Saint Louis, MO, USA); anti-β3 from Abcam (Cambridge, UK); and anti-β4 from Millipore (Merck Millipore, Oxford, UK).



    Similar Products

    p-axl antibodies (y702)  (Cell Signaling Technology Inc)
    90
    Cell Signaling Technology Inc p-axl antibodies (y702)
    P Axl Antibodies (Y702), supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/p-axl+antibodies+(y702)/anti+axl/pm38886556-70-1-7
    Average 90 stars, based on 1 article reviews
    p-axl antibodies (y702) - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    p-axl(y702) #5724 antibody  (Cell Signaling Technology Inc)
    90
    Cell Signaling Technology Inc p-axl(y702) #5724 antibody
    P Axl(y702) #5724 Antibody, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/p-axl+antibodies+(y702)/anti+axl/pm38886556-57-4-20
    Average 90 stars, based on 1 article reviews
    p-axl(y702) #5724 antibody - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    antibodies against p-axl (y702), axl, p-akt (s473), akt, p-stat3(y705), stat3, p-erk(y202/204), erk, gapdh  (Cell Signaling Technology Inc)
    90
    Cell Signaling Technology Inc antibodies against p-axl (y702), axl, p-akt (s473), akt, p-stat3(y705), stat3, p-erk(y202/204), erk, gapdh
    Antibodies Against P Axl (Y702), Axl, P Akt (S473), Akt, P Stat3(y705), Stat3, P Erk(y202/204), Erk, Gapdh, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/p-axl+antibodies+(y702)/anti+axl/pmc10692477-233-18-19
    Average 90 stars, based on 1 article reviews
    antibodies against p-axl (y702), axl, p-akt (s473), akt, p-stat3(y705), stat3, p-erk(y202/204), erk, gapdh - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    antibodies against p-axl (y702  (Cell Signaling Technology Inc)
    90
    Cell Signaling Technology Inc antibodies against p-axl (y702
    Antibodies Against P Axl (Y702, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/p-axl+antibodies+(y702)/anti+axl/pmc07319943-34-4-14
    Average 90 stars, based on 1 article reviews
    antibodies against p-axl (y702 - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    p -axl(d12b2)(y702)_r_v antibody  (Cell Signaling Technology Inc)
    90
    Cell Signaling Technology Inc p -axl(d12b2)(y702)_r_v antibody
    P Axl(d12b2)(Y702) R V Antibody, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/p-axl+antibodies+(y702)/rabbit+anti+human+a%CE%B2+antibody+clone+d12b2/pmc05605756-15-7-3
    Average 90 stars, based on 1 article reviews
    p -axl(d12b2)(y702)_r_v antibody - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    y702  (Cell Signaling Technology Inc)
    93
    Cell Signaling Technology Inc y702
    Y702, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/p-axl+antibodies+(y702)/Aurora+A%2FAIK+Antibody/10__1523_slash_eneuro__0272___17__2017-127-75-76
    Average 93 stars, based on 1 article reviews
    y702 - by Bioz Stars, 2026-10
    93/100 stars
    		  Buy from Supplier
    abs against p-axl(y702) (rabbit) antibody  (Cell Signaling Technology Inc)
    90
    Cell Signaling Technology Inc abs against p-axl(y702) (rabbit) antibody
    Abs Against P Axl(y702) (Rabbit) Antibody, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/p-axl+antibodies+(y702)/anti+axl/pm26356564-183-0-17
    Average 90 stars, based on 1 article reviews
    abs against p-axl(y702) (rabbit) antibody - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier

    Image Search Results